St. Luke's Health’s Post

❤️ Heart Care Revolution! Huge Achievements have been reached with the First Successful Implantation of BiVACOR's Total Artificial Heart (TAH). We are thrilled to share a groundbreaking achievement in the field of cardiac care! The Texas Heart Institute and BiVACOR have successfully implanted the BiVACOR Total Artificial Heart (TAH) in a human for the first time. This innovative device, designed to replace both ventricles of a failing heart, represents a beacon of hope for patients with severe heart failure awaiting transplants. 👩🔬 This milestone not only showcases the incredible advancements in med tech but also brings us one step closer to providing life-saving solutions for countless individuals. The BiVACOR TAH, with its advanced design and magnetic levitation technology, promises to transform the future of heart failure therapy. We are immensely proud of the dedicated teams at The Texas Heart Institute, BiVACOR, Baylor College of Medicine, and CHI St. Luke's Health - Baylor St. Luke's Medical Center for their unwavering commitment to improving patient outcomes. Together, they are pioneering a new era in cardiac medicine and offering renewed hope to those in need. 🗓 This is a huge testament to why our industry work is so rewarding and how leveraging partnerships can speed up timelines for patients who need it most, AMAZING WORK! #Innovation #Healthcare #MedicalBreakthrough #HeartFailure #CardiacCare #Biotechnology" Read more below and share your thoughts! https://lnkd.in/dRiUxxPw

Discover the latest heart health advancements that are making a difference, as shared by the AAMC. From groundbreaking treatments like TAVR and innovative medications such as SGLT2 inhibitors to life-saving procedures for congenital heart defects, these five key developments are transforming cardiac care. A must-read for healthcare professionals. #HeartHealth #MedicalInnovation #AAMC

Generating a Better Probability of Success for the High Stakes-driven Cardiovascular Space https://lnkd.in/g3A_9-EQ Biosense Webster Johnson & Johnson Luigi Di Biase, MD, PhD, FACC, FHRS Jasmina Beslagic Brooks #CardiovascularHealth, #Healthcare, #Medical, #FDA, #MedicalDevices. #HealthcareDiagnostics, #HealthcareImaging, #3DTechnology, #UltrasoundTechnology

Groundbreaking Medical Achievement Alert! The Texas Heart Institute (THI), in collaboration with BiVACOR®, Baylor St. Luke’s Medical Center, and Baylor College of Medicine, has successfully performed the first-in-human implantation of the BiVACOR Total Artificial Heart (TAH) as part of the FDA Early Feasibility Study! This advanced TAH, utilizing cutting-edge MAGLEV technology, represents a significant leap forward in cardiac care, offering new hope to patients with severe heart failure awaiting transplants. This groundbreaking procedure, using a titanium rotary blood pump with advanced MAGLEV technology, represents a significant milestone in cardiac care, providing a vital bridge-to-transplant solution for patients awaiting heart transplants. US20230173253A1 The BiVACOR Total Artificial Heart (TAH) operates using advanced MAGLEV (magnetic levitation) technology. The device consists of a titanium rotary blood pump with a single moving part—a magnetically levitated rotor. This rotor, positioned between two pump chambers, propels blood to both the pulmonary (lungs) and systemic (body) circulations, effectively replacing the function of both ventricles of a failing heart. The MAGLEV system eliminates mechanical wear, reduces blood trauma, and provides a durable, reliable, and biocompatible heart replacement for patients awaiting a heart transplant. AU2017205172B2 The heart pump described in the patent is a rotary impeller-based device designed to assist or replace the function of the heart. It includes a housing that forms a cavity with at least one inlet and one outlet. An impeller with vanes is positioned inside the cavity, which rotates to move fluid (blood) from the inlet to the outlet. The device is engineered to maintain a minimal cross-sectional flow path area, reducing shear stress and the risk of blood cell damage, clotting, or pump thrombosis. The pump is designed to be efficient and biocompatible, providing stable and controlled blood flow, essential for balancing systemic and pulmonary circulations. #HeartHealth #MedicalInnovation #Cardiology #Baylor #THI #BiVACOR

The RECOVER IV randomized trial has been stopped early for ethical reasons. Read more on #CRTonline. https://lnkd.in/eNhaUVd2 #cardiacnurse #cardiologists #cardiology #cardiologyfellow #cardiologyfellows #cardiologynurse #cardiologynurses #cathlab #cathlabnurse #cathlabtech #interventionalcardiologists #interventionalcardiology #interventionalcardiologyfellow #interventionalcardiologyfellows #MCRN #medicalequity

Two promising takeaways for the #privateequity #cardiology space: CMS added 23 ASC cardiac cath and PCI codes in the last two years. There are a minimum of 12 PE firms targeting cardiology and 6 acquisition focused CV practice platforms making 9 acquisitions the first half of 2023, matching 2021 and 2022’s totals combined and SURPASSING full year 2018-2020 combined. Here’s to 2024!

Cardiovascular care has the potential to be transformed by innovation! In a recent article authored by Bernardo Perez Villa, MD, MSc, Senior Engagement Partner, Innovations, Florida Market, highlights three technologies in development with Cleveland Clinic Innovations that are poised to reshape how we address cardiovascular diseases. “It is vital to keep up with cutting-edge developments in the dynamic field of cardiovascular medicine, and many startups armed with pre-market technologies are ready to transform cardiovascular healthcare,” shared Dr. Perez-Villa. “Here, we present three promising technologies that may reshape how we address cardiovascular diseases.” Cleveland Clinic Innovations portfolio companies Advanced NanoTherapies, Inc, Cardionomic Inc., and Mitria Medical, are featured. These innovations represent a significant leap forward in cardiovascular medicine, promising to improve patient care and outcomes. 💓 https://hubs.li/Q02Mc8nN0 #CardiovascularCare #MedicalInnovation #HealthcareTechnology #PatientOutcomes #ClevelandClinic

The ACC 2024 meeting is now complete, after over 17,000 #cardiology professionals converged in Atlanta to witness cardiovascular medicine evolve in front of their eyes. Among dozens of highlights, here are the Cardiac Wire’s eight biggest trends emerging from #ACC24. https://lnkd.in/ga_9P7v7

Dive into the future of cardiology with MedAxiom and American College of Cardiology! 🚀 Join the conversation as we explore the evolving landscape of cardiovascular care, from value-based approaches to navigating the impact of private equity. 💡 Tune in to the ACCEL audio interview featuring Jerry Blackwell, MD, MBA, FACC, and Joseph Marine, MD, MBA, FACC, for insights on shaping the future of patient-centric healthcare: https://hubs.li/Q02tRZ8D0 #CardiologyFuture #ValueBasedCare #HealthcareInnovation

Removal of fasting requirements before cardiac procedures is not only safe, but also results in more satisfied patients, say the SCOFF trial investigators. Read more from #ESC2024 on #CRTonline. https://ow.ly/QfT150TgTsp #cardiacnurse #cardiologists #cardiology #cardiologyfellow #cardiologyfellows #cardiologynurse #cardiologynurses #cathlab #cathlabnurse #cathlabtech #interventionalcardiologists #interventionalcardiology #interventionalcardiologyfellow #interventionalcardiologyfellows #MCRN #medicalequity #womenincardiology #womeninmedicine